Histologic muscular history in steroid-treated and untreated patients with Duchenne dystrophy

Neurology

Volumn 85, Issue 21, 2015, Pages 1886-1893

  Peverelli, Lorenzo ^a   Testolin, Silvia ^a   Villa, Luisa ^a   D'Amico, Adele ^b   Petrini, Stefania ^c   Favero, Chiara ^e   Magri, Francesca ^e   Morandi, Lucia ^f   Mora, Marina ^f   Mongini, Tiziana ^g   Bertini, Enrico ^d   Sciacco, Monica ^a   Comi, Giacomo P ^e   Moggio, Maurizio ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b Laboratory of Molecular Medicine for Muscular and Neurodegenerative Diseases   (Italy)

^c Laimburg Post Auer   (Italy)

^d BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f DEPARTMENT OF NEUROSURGERY   (Italy)

^g UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID;

ARTICLE; CHILD; CLINICAL EVALUATION; CONNECTIVE TISSUE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MUSCLE BIOPSY; MUSCLE CELL; MUSCLE DISEASE; MUSCLE HYPERTROPHY; MUSCLE TISSUE; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STEROID THERAPY; TISSUE STRUCTURE; BIOPSY; CROSS-SECTIONAL STUDY; DRUG EFFECTS; INFANT; MALE; MUSCLE STRENGTH; MUSCULAR DYSTROPHY, DUCHENNE; PATHOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; SKELETAL MUSCLE; TREATMENT OUTCOME;

BIOPSY; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; HUMANS; INFANT; MALE; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; RETROSPECTIVE STUDIES; STEROIDS; TREATMENT OUTCOME;

EID: 84947998222     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002147     Document Type: Article

References (39)

1. Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirs-en for the treatment of Duchenne muscular dystrophy. Ann Neurol 2013;74:637-647.
2. Hoffman EP, Reeves E, Damsker J, et al. Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy. Phys Med Rehabil Clin N Am 2012;23:821-828.
3. Finkel RS, Flanigan KM, Wong B, et al. Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PLoS One 2013;8 e81302.
4. ClinicalTrials.gov. Available at: www.Clinicaltrials.gov. Accessed February 20, 2015.
5. Goemans NM, Tulinius M, van den Akker JT, et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011;364:1513-1522.
6. Govoni A, Magri F, Brajkovic S, et al. Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy. Cell Mol Life Sci 2013;70:4585-4602.
7. Buyse GM, Van der Mieren G, Erb M, et al. Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance. Eur Heart J 2009;30:116-124.
8. Buyse GM, Goemans N, van den Hauwe M, et al. Idebe-none as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial. Neuromuscul Disord 2011;21:396-405.
9. European Medicines Agency. Available at: www.ema. europa.eu. Accessed February 20, 2015.
10. Desguerre I, Mayer M, Leturcq F, et al. Endomysial fibro-sis in Duchenne muscular dystrophy: a marker of poor outcome associated with macrophage alternative activation. J Neuropathol Exp Neurol 2009;68:762-773.
11. Bell CB, Conen PE. Histopathological changes in Duchenne muscular dystrophy. J Neurol Sci 1968;7:529-540.
12. Dubowitz V, Sewry CA, Lane RJM. Muscle Biopsy: A Practical Approach, 3rd ed. Philadelphia: Saunders Elsevier; 2007.
13. Prelle A, Comi GP, Tancredi L, et al. Sarcoglycan deficiency in large Italian population of myopathic patients. Acta Neuropathol 1998;96:509-514.
14. Hankinson SE, Manson JE, Spiegelman D, et al. Repro-ducibility of plasma hormone levels in postmenopausal women over a two to three year period. Cancer Epidemiol Biomarkers Prev 1995;4:649-654.
15. Gabellini D, D'Antona G, Moggio M, et al. Facioscapu-lohumeral muscular dystrophy in mice overexpressing FRG1. Nature 2006;439:973-977.
16. Mendel J, Sahenk Z, Malik1 V, et al. A phase 1/2a folli-statin gene therapy trial for Becker muscular dystrophy. Mol Ther 2015;23:192-201.
17. Collins TJ. ImageJ for microscopy. Biotechniques 2007;43 (1 suppl):25-30.
18. Fortin M, Battié MC. Quantitative paraspinal muscle measurements: inter-software reliability and agreement using OsiriX and ImageJ. Phys Ther 2012;92:853-864.
19. Klein CJ, Coovert DD, Bulman DE, Ray PN, Mendell JR, Burghes AH. Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. Am J Hum Genet 1992;50:950-959.
20. Thanh LT, Nguyen TM, Helliwell TR, Morris GE. Characterization of revertant muscle fibers in Duchenne muscular dystrophy, using exon-specific monoclonal antibodies against dystrophin. Am J Hum Genet 1995;56:725-731.
21. Uchino M, Tokunaga M, Mita S, et al. PCR and immu-nocytochemical analyses of dystrophin-positive fibers in Duchenne muscular dystrophy. J Neurol Sci 1995;129: 44-50.
22. Fanin M, Danieli GA, Vitiello L, Senter L, Angelini C. Prevalence of dystrophin positive fibers in 85 Duchenne muscular dystrophy patients. Neuromuscul Disord 1992; 2:41-45.
23. Arechavala-Gomeza V, Kinali M, Feng L, et al. Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials. Neuromuscul Disord 2010;20:295-301.
24. Emery AE. Muscle histology and creatine kinase levels in the foetus in Duchenne muscular dystrophy. Nature 1977; 266:472-473.
25. Toop J, Emery AE. Muscle histology in fetuses at risk for Duchenne muscular dystrophy. Clin Genet 1974;5:230-233.
26. Giordani L, Puri PL. Epigenetic control of skeletal muscle regeneration integrating genetic determinants and environmental changes. FEBS J 2013;280:4014-4025.
27. Sartorelli V, Juan AH. Sculpting chromatin beyond the double helix: epigenetic control of skeletal myogenesis. Curr Top Dev Biol 2011;96:57-83.
28. Bharathy N, Ling BM, Taneja R. Epigenetic regulation of skeletal muscle development and differentiation. Subcell Biochem 2013;61:139-150.
29. Palacios D, Mozzetta C, Consalvi S, et al. TNF/p38a/polycomb signalling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. Cell Stem Cell 2010;7:455-469.
30. Dilworth FJ, Blais A. Epigenetic regulation of satellite cell activation during muscle regeneration. Stem Cell Res Ther 2011;2:18.
31. Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006;16:249-255.
32. Bushby K, Muntoni F, Urtizberea A, Huges R, Griggs R. Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of cortico-steroids. Neuromuscul Disord 2004;14:526-534.
33. Engel AG. Myology, 3rd ed. New York: McGraw-Hill; 2004.
34. Eiholzer U, Boltshauser E, Frey D, Molinari L, Zachmann M. Short stature: a common feature in Duchenne muscular dystrophy. Eur J Pediatr 1988;147:602-605.
35. McDonald CM, Henricson EK, Abresch RT, et al. The 6-Minute Walk Test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve 2013;48:343-356.
36. Zatz M, Rapaport D, Vainzof M, et al. Serum creatine-kinase (CK) and pyruvate-kinase (PK) activities in Duchenne (DMD) as compared with Becker (BMD) muscular dystrophy. J Neurol Sci 1991;102:190-196.
37. Mozzetta C, Consalvi S, Saccone V, et al. Fibroadipo-genic progenitors mediate the ability of HDAC inhibitors to promote regeneration in dystrophic muscles of young, but not old Mdx mice. EMBO Mol Med 2013;5:626-639.
38. Finanger EL, Russman B, Forbes SC, Rooney WD, Walter GA, Vandenborne K. Use of skeletal muscle MRI in diagnosis and monitoring disease progression in Duchenne muscular dystrophy. Phys Med Rehabil Clin N Am 2012;23:1-10.
39. Hollingsworth KG, Garrood P, Eagle M, Bushby K, Straub V. Magnetic resonance imaging in Duchenne muscular dystrophy: longitudinal assessment of natural history over 18 months. Muscle Nerve 2013;48:586-588.